Thermo Fisher Scientific Inc Common Stock (TMO)
Stock · NYSE · Industrials
$690as of 10/16/2026
Price chart
Active signals
TMO Signal Track Record
How signals performed across all stocks →What TMO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| 200-Day Moving Average TouchActive now | 27 | +1.2% | 56% | July 17, 2026 |
| Bollinger Band Breakout | 25 | +3.5% | 60% | September 16, 2026 |
| Volume Spike | 20 | +2.5% | 60% | September 2, 2026 |
| Bollinger Band Breakdown | 19 | -1.9% | 42% | March 12, 2026 |
| Any 20-session window (baseline) | +0.5% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TMO
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for bi…
- Sector
- Industrials
- Industry
- Industrial Machinery/Components
- Employees
- 125,000
Fundamentals
- 1-day range
- $652.5$662.52
- Market cap
- $214.46B
- P/E (trailing)
- 35.60
- P/E (forward)
- 24.01
- EPS (trailing)
- $18.57
- Dividend yield
- 0.29%
- Beta
- 0.86
- Avg. volume
- 2.08M
- Ex-dividend date
- September 15, 2026
- Dividend pay date
- October 15, 2026
How Thermo Fisher Scientific Inc Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
25 analyst ratings
Thermo Fisher Scientific Inc Common Stock Competitors
Chosen by industry and closest market cap.
- TMOThermo Fisher Scientific Inc Common Stock$690▼ 0.93%Market cap $214.46BP/E 35.60$435.27$694.33
- ETNEaton Corporation PLC Ordinary Shares$391.25▼ 2.79%Market cap $174.08BP/E 39.68$311.92$478
- DEDeere & Company Common Stock$641.86▼ 1.35%Market cap $165.97BP/E 35.92$433$721.22
- DHRDanaher Corporation Common Stock$229.04▼ 1.06%Market cap $140.58BP/E 39.43$160.93$242.8
- VRTVertiv Holdings LLC Class A Common Stock$206.42▼ 3.88%Market cap $105.94BP/E 47.50$147.82$379.94
- JCIJohnson Controls International plc Ordinary Share$145.47▼ 1.46%Market cap $93.62BP/E 24.57$104.49$160.41
- CMICummins Inc. Common Stock$531.33▼ 0.26%Market cap $88.65BP/E 26.28$400.72$737.76
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific Inc Common Stock | $214.46B | 35.60 | $690 | ▼ 0.93% | $435.27$694.33 |
| ETN Eaton Corporation PLC Ordinary Shares | $174.08B | 39.68 | $391.25 | ▼ 2.79% | $311.92$478 |
| DE Deere & Company Common Stock | $165.97B | 35.92 | $641.86 | ▼ 1.35% | $433$721.22 |
| DHR Danaher Corporation Common Stock | $140.58B | 39.43 | $229.04 | ▼ 1.06% | $160.93$242.8 |
| VRT Vertiv Holdings LLC Class A Common Stock | $105.94B | 47.50 | $206.42 | ▼ 3.88% | $147.82$379.94 |
| JCI Johnson Controls International plc Ordinary Share | $93.62B | 24.57 | $145.47 | ▼ 1.46% | $104.49$160.41 |
| CMI Cummins Inc. Common Stock | $88.65B | 26.28 | $531.33 | ▼ 0.26% | $400.72$737.76 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Dividend Champion, Contender, And Challenger Highlights: Week October 11SeekingAlpha · 10/9/2026
- Thermo Fisher Scientific's Q3 2026 Earnings: What to ExpectYahoo · 10/9/2026
- What Could Thermo Fisher Scientific (TMO) Change With Its New Digital CMC Consortium?Yahoo · 10/8/2026
- Which S&P500 stocks are gapping on Thursday?ChartMill · 10/8/2026
- Why Thermo Fisher Scientific (TMO) Is Back In The SpotlightYahoo · 10/8/2026
- PCR Market Report Forecasts qPCR, Digital PCR and Multiplex Testing Growth, Profiling 89 Companies Including Roche and Thermo FisherYahoo · 10/8/2026
- Pharmaceutical CRO Market Forecasts Growth from $45.33B (2025) to $83.31B by 2033, Profiling IQVIA, ICON, Thermo Fisher, Medpace & 5 Other Key PlayersYahoo · 10/8/2026
- Quantum BioPharma (QNTM) Enlists Thermo Fisher's Clinical Research Business to Launch Phase 2 Lucid-MS TrialYahoo · 10/7/2026
Insider Activity
Insider Actions →- R. Alexandra Keith · September 26, 2026 · Grant46
- Dion J. Weisler · September 26, 2026 · Grant56
- Karen S. Lynch · September 26, 2026 · Grant46
- Scott M. Sperling · September 26, 2026 · Grant63
- Jennifer M. Johnson · September 26, 2026 · Grant46
- Gianluca Pettiti · August 31, 2026 · Option Exercise3.7K @ $309.63
- Gianluca Pettiti · August 31, 2026 · Sale3.7K @ $614.38
- Gianluca Pettiti · August 31, 2026 · Sale400 @ $614.38
- Michael D. Shafer · August 28, 2026 · Tax Withholding162 @ $622.18
- Marc N. Casper · August 28, 2026 · Tax Withholding725 @ $622.18
- Meyer James · August 28, 2026 · Tax Withholding114 @ $622.18
- Meyer James · August 28, 2026 · Tax Withholding55 @ $622.18
- Meyer James · August 28, 2026 · Tax Withholding20 @ $622.18
- Meyer James · August 28, 2026 · Tax Withholding44 @ $622.18
- Meyer James · August 28, 2026 · Tax Withholding37 @ $622.18
Institutional Ownership
March 31, 2026
- Total shares held
- 318.91M
- Total value held
- $150.94B
- Institutional holders
- 2572
- Unknown30.45M
- Unknown24.28M
- Unknown16.73M
- Unknown10.86M
- Unknown10.78M
- Unknown8.41M
- Unknown6.81M
- Unknown6.65M
- Unknown6.32M
- Unknown5.53M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Thermo Fisher Outperforms on Life Sciences Recovery
Thermo Fisher Scientific reported strong results driven by a recovery in the life sciences sector. Growth in academic and government spending is supporting demand for the company's products. Analysts note that increasing omics demand could further influence the stock's outlook.
Thermo Fisher Outperforms on Life Sciences Recovery. Thermo Fisher Scientific reported strong results driven by a recovery in the life sciences sector. Growth in academic and government spending is supporting demand for the company's products. Analysts note that increasing omics demand could further influence the stock's outlook.